MARKET

MTNB

MTNB

Matinas
AMEX

Real-time Quotes | Nasdaq Last Sale

1.050
+0.148
+16.46%
After Hours: 1.040 -0.01 -0.95% 16:19 11/27 EST
OPEN
0.9500
PREV CLOSE
0.9016
HIGH
1.070
LOW
0.9300
VOLUME
6.40M
TURNOVER
--
52 WEEK HIGH
2.490
52 WEEK LOW
0.4900
MARKET CAP
209.21M
P/E (TTM)
-8.6993
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Matinas BioPharma (MTNB) Looks Good: Stock Adds 8.6% in Session
Matinas BioPharma (MTNB) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Zacks · 1d ago
Matinas Bio secures $3.75M grant to support development of MAT2501
Matinas BioPharma (MTNB) has been awarded up to $3.75M from the Cystic Fibrosis Foundation ((CFF)) to support preclinical development of MAT2501, company's lipid nano-crystal oral formulation of aminoglycoside amikacin to
Seekingalpha · 11/20 12:18
Matinas BioPharma Awarded up to $3.75M from the Cystic Fibrosis Foundation to Support Development of Oral Amikacin For The Treatment of NTM Infections in Cystic Fibrosis Patients
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need,
Benzinga · 11/20 12:01
Matinas BioPharma to Participate in Annual Piper Sandler Healthcare Conference
BEDMINSTER, N.J., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, has been invited to participate in a fireside chat as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held December 1-3, 2020. The Company will also host investor meetings during the conference. The pre-recorded fireside chat will be available on the IR Calendar page of the Investors section of the Company’s website (www.matinasbiopharma.com) beginning November 23, 2020. A webcast replay will be accessible for 90 days following the event. About Matinas BioPharma Matinas BioPharma is a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care for patients in areas of significant unmet medical need. Company leadership has a deep history and knowledge of drug development and is supported by a world-class team of scientific advisors.MAT9001, the Company’s lead product candidate for the treatment of cardiovascular and metabolic conditions, is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, under development for hypertriglyceridemia. MAT9001 is currently in a second head-to-head comparative study against Vascepa® (ENHANCE-IT), with topline data expected in the first quarter of 2021.In addition, Matinas is developing a portfolio of products based upon its proprietary lipid nano-crystal (LNC) drug delivery platform, which can solve complex challenges relating to the safe and effective delivery of potent medicines, making them more targeted, less toxic and orally bioavailable.MAT2203, the Company’s lead product candidate utilizing its LNC platform, is an oral, encochleated formulation of the well-known, but highly toxic, antifungal medicine amphotericin B, to treat serious invasive fungal infections. MAT2203 is currently in a Phase 2 open-label, sequential cohort study (EnACT) in HIV-infected patients with cryptococcal meningitis. EnACT is set to begin enrolling patients in its second cohort, with the next DSMB evaluation of safety and efficacy data anticipated to occur in the middle of 2021.Forward Looking StatementsThis release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company’s anticipated capital and liquidity needs, strategic focus and the future development of its product candidates, including MAT2203 and MAT2501, the anticipated timing of regulatory submissions, the anticipated timing of clinical studies, the anticipated timing of regulatory interactions, the Company’s ability to identify and pursue development and partnership opportunities for its products or platform delivery technology on favorable terms, if at all, and the ability to obtain required regulatory approval and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could," "believes," "estimates" and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company’s intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company’s products; and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma’s product candidates are all in a development stage and are not available for sale or use.Investor and Media Contacts Peter Vozzo Westwicke 443-213-0505 peter.vozzo@westwicke.comIan Cooney Director – Investor Relations & Corporate Development Matinas Biopharma, Inc. (415) 722-4563 icooney@matinasbiopharma.com
GlobeNewswire · 11/19 21:15
Matinas BioPharma Hldgs Q3 EPS $(0.03), Inline, Sales $95.83K Beat $20.00K Estimate
Matinas BioPharma Hldgs (AMEX:MTNB) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of
Benzinga · 11/06 12:09
Matinas Biopharma EPS in-line, beats on revenue
Matinas Biopharma (MTNB): Q3 GAAP EPS of -$0.03 in-line.Revenue of $0.09M beats by $0.07M.Shares +4.09% PM.Press Release
Seekingalpha · 11/06 11:42
FDA on board with late-stage program for Matinas Bio omega-3 therapy
Matinas BioPharma ([[MTNB]] +2.2%) confirms that the FDA agrees with the key steps in its planned Phase 3 program for prescription omega-3 therapy MAT9001 for the potential treatment of patients with
Seekingalpha · 09/15 13:36
Matinas BioPharma Appoints Industry Veteran Natasha Giordano to Board of Directors
BEDMINSTER, N.J., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced the appointment of Natasha Giordano to its Board of Directors as an independent director and a member of the audit committee, effective Monday, September 14, 2020. Ms. Giordano brings
GlobeNewswire · 09/14 11:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MTNB. Analyze the recent business situations of Matinas through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MTNB stock price target is 3.383 with a high estimate of 5.00 and a low estimate of 1.800.
EPS
Institutional Holdings
Institutions: 50
Institutional Holdings: 32.50M
% Owned: 16.31%
Shares Outstanding: 199.25M
TypeInstitutionsShares
Increased
8
1.69M
New
5
268.22K
Decreased
14
4.48M
Sold Out
11
2.85M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.18%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Independent Director
Herbert Conrad
President/Chief Executive Officer/Director
Jerome Jabbour
Vice Chairman/Independent Director
Patrick LePore
Chief Financial Officer
Keith Kucinski
Chief Scientific Officer
Raphael Mannino
Other
James Ferguson
Other
Theresa Matkovits
Independent Director
Eric Ende
Independent Director
Natasha Giordano
Independent Director
James Scibetta
Independent Director
Matt Wikler
Independent Director
Matthew Wikler
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About MTNB
Matinas BioPharma Holdings, Inc., is a development stage biopharmaceutical company. The Company focuses on identifying and developing novel pharmaceutical products. The Company's technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, which is designed to make safer, more tolerable, less toxic and orally bioavailable. The Company's technology combines the use of lipids as active pharmaceutical ingredients (APIs) and the use of lipids in cochleate-shaped lipid-crystal nano-particle drug delivery vehicles. The Company’s product candidates include, MAT2203 and MAT2501.The Company's anti-infective product candidate, MAT 2203, is an application of its cochleate delivery technology to a spectrum anti-fungal drug called amphotericin B. The Company's MAT2501 is an orally administered, encochleated formulation of the spectrum IV-only aminoglycoside antibiotic agent amikacin, utilizes the Company's lipid-crystal, nanoparticle delivery technology.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Matinas BioPharma Holdings Inc stock information, including AMEX:MTNB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MTNB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MTNB stock methods without spending real money on the virtual paper trading platform.